This is an old revision of the document!
Robin Robinson
On the C-SPAN Networks - Robin Robinson is a Vice President for Scientific Affairs in the RenovaCare with five videos in the C-SPAN Video Library; the first appearance was a 2009 Speech as a Director for (BARDA) Biomedical Advanced Research and Development Authority in the Department of Health and Human Services.
The year with the most videos was 2014 with two videos as a Deputy Assistant Secretary for the Office of the Assistant Secretary for Preparedness and Response in the Department of Health and Human Services.
The year with the highest average number of views per program was 2019 with an average of 15,267 views per program.
Appearances by Title - c. September 1, 2019 - Present Vice President, Scientific Affairs, RenovaCare Videos: 1
Previously Director, Biomedical Advanced Research and Development Authority, Department of Health and Human Services c. April 1, 2008 - c. January 20, 2009 Videos: 3
Deputy Assistant Secretary, Office of the Assistant Secretary for Preparedness and Response, Department of Health and Human Services c. April 1, 2008 - c. January 20, 2009 Videos: 1 1)
C-SPAN Congressional Testimony
December 11, 2009 - Advances in Influenza Vaccine Technologies
The Department of Health and Human Services held a seminar to familiarize the media with government research on new
People in this video -
Francis Collins M.D. - Director National Institutes of Health
Anthony Fauci M.D. - Director National Institute of Allergy and Infectious Diseases
Bruce Gellin - Program Director Department of Health and Human Services National Vaccine Program
Jesse Goodman M.D. - Deputy Commissioner U.S. Food and Drug Administration
Bill Hall - Director Department of Health and Human Services News Division
Carole A. Heilman Director National Institute of Allergy and Infectious Diseases Division of Microbiology and Infectious Diseases
Gary Nabel M.D. - Director National Institutes of Health Vaccine Research Center
Robin Robinson Director Department of Health and Human Services - Biomedical Advanced Research and Development Authority
Jerry Weir - Director U.S. Food and Drug Administration - Viral Products Division 2)
September 16, 2014 - West Africa Ebola Outbreak
Federal health officials and health workers testified at a joint hearing of the Senate Health, Education, Labor and Pensions
October 16, 2014 - U.S. Response to Ebola
Centers for Disease Control and Prevention (CDC) Director Tom Frieden and other federal health officials testified
November 19, 2015 - Influenza Season Preparedness
Public health agency officials testified on their organizations' preparations for the upcoming influenza season and other infectious diseases. Representative Degette (D-CO) questioned the continued use of egg-based technology instead of cellular and if the U.S. would be nimble enough to use newer technologies if there was a pandemic.
People in this video
Carole A. Heilman - Director National Institute of Allergy and Infectious Diseases Division of Microbiology and Infectious Diseases
Karen Midthun M.D. - Director U.S. Food and Drug Administration Center for Biologics Evaluation and Research
Frank Pallone Jr. - U.S. Representative [D] New Jersey
Robin Robinson - Director Department of Health and Human Services Biomedical Advanced Research and Development Authority (BARDA)
Anne Schuchat M.D. - Principal Deputy Director Centers for Disease Control and Prevention Agency for Toxic Substances and Disease Registry
Susan W. Brooks - U.S. Representative [R] Indiana
Chris Collins - U.S. Representative [R] New York
Diana DeGette - U.S. Representative [D] Colorado
Gene Green - U.S. Representative [D] Texas
Morgan Griffith - U.S. Representative [R] Virginia
Markwayne Mullin - U.S. Representative [R] Oklahoma
Tim Murphy - U.S. Representative [R] Pennsylvania 3)
Flu Vaccine Science and Innovation
The House Science, Space and Technology Committee held a hearing with public health officials on efforts to improve flu vaccines and develop a universal flu vaccine.
The witnesses in the first panel were Dr. Anthony Fauci, National Institute of Allergy and Infectious Diseases director, and Dr. Daniel Jernigan, director of the Center for Disease Control and Prevention (CDC) Influenza Division.
The second panel comprised former Health and Human Services Director for Influenza Robin Robinson and Pennsylvania Health Department Bureau of Epidemiology Director Sharon Watkins.
People in this video
Brian Babin - U.S. Representative [R] Texas
Jim Baird - U.S. Representative [R] Indiana
Ami Bera M.D. - U.S. Representative [D] California
Suzanne Bonamici - U.S. Representative [D] Oregon
Sean Casten - U.S. Representative [D] Illinois
Steve Cohen - U.S. Representative [D] Tennessee
Anthony S. Fauci M.D. - Director National Institute of Allergy and Infectious Diseases
Bill Foster - U.S. Representative [D] Illinois
Anthony Gonzalez - U.S. Representative [R] Ohio
Daniel Jernigan M.D. - Director Centers for Disease Control and Prevention Influenza Division
Eddie Bernice Johnson - U.S. Representative [D] Texas
Frank D. Lucas - U.S. Representative [R] Oklahoma
Jerry McNerney - U.S. Representative [D] California
Bill Posey - U.S. Representative [R] Florida
Robin Robinson - Vice President RenovaCare Scientific Affairs
Haley Stevens - U.S. Representative [D] Michigan
Sharon Watkins - Director Pennsylvania Department of Health Bureau of Epidemiology
Jennifer Wexton - U.S. Representative [D] Virginia 4)
Full hearing Housatonic Rumble 5)
Dr. Robin Robinson, Founding Director of BARDA Joins RenovaCare
SCOTTSDALE, Ariz., Aug. 20, 2019 (GLOBE NEWSWIRE) – RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), developer of patented technologies for spraying self-donated stem cells for the regeneration of tissues and organs, is pleased to announce the appointment of its Vice President of Scientific Affairs, Dr. Robin A. Robinson, a respected authority on the development of breakthrough biomedical technologies, for which he was cited in 2018 as one of the top 100 innovators in medicine by The Medicine Maker.
Notably, Dr. Robinson was appointed as Director of the Biomedical Advanced Research and Development Authority (BARDA), with an annual budget of $1.35 billion and a staff of 250 scientists and medical experts. He brought BARDA into prominence as one of the top 10 fully integrated R&D organizations worldwide supporting advanced development and acquisition of more than 240 drugs, vaccines, diagnostics, and medical devices for man-made biodefense threats, pandemic influenza, and emerging infectious diseases including Ebola and Zika viruses. 32 of these medical countermeasure products that BARDA supported were approved and licensed by the FDA during his 12-year tenure.
During his tenure at BARDA, Dr. Robinson oversaw the funding of over $535 million in contracts for skin regeneration, burns, stem cell therapies, and related technologies for thermal and radiation burn wounds.
At RenovaCare, Dr. Robinson will oversee and direct the Company’s strategy, execution and engagement with government agencies, commercial research groups, academic institutions and select opinion leaders.
“The patented RenovaCare SkinGun™ technology and its ability to ultra-gently spray stem cells could present a special opportunity for investigations and applications in a wide range of regenerative therapies,” stated Dr. Robin Robinson, newly appointed Vice President of Scientific Affairs at RenovaCare, Inc.
“I look forward to working with the RenovaCare team as we capitalize on this very exciting cell deposition innovation.”
“We’re privileged to have won Dr. Robinson’s confidence in our SkinGun™ technology, especially as we advance our regulatory program, push towards eventual commercialization, and expand our product and clinical pipelines,” stated Mr. Jay S. Bhogal, Chief Operating Officer at RenovaCare.
Dr. Robinson’s appointment follows last week’s award of a new patent to RenovaCare, allowing its SkinGun™ to now spray all varieties of tissues and cells, and thus opening the door for its potential application in regenerative applications beyond skin.
Recent breakthroughs in stem cell therapies include the regeneration of human organs, tissues and bone. RenovaCare believes that the ultra-gentle spray-on application of such cells could be investigated and developed by way of commercial and academic collaborations, an area of Dr. Robinson’s expertise.
Dr. Robin Robinson is a consummate dealmaker, having successfully established over 60 partnerships with federal agencies, including the United States Food and Drug Administration (FDA), Centers for Disease Control and Prevention, National Institutes of Health, The Defense Advanced Research Projects Agency (DARPA), The Joint Program Executive Office for Chemical and Biological Defense, and the Defense Threat Reduction Agency.
His non-governmental and more than 80 commercial partnerships included the Bill & Melinda Gates Foundation, Wellcome Trust, Sanofi, GlaxoSmithKline plc, Novartis, Merck, Roche/Genentech, Amgen, Johnson & Johnson (Crucell), SIGA, Regeneron and Emergent BioSolutions.
Dr. Robinson developed collaborations with universities and foreign governments, including the Johns Hopkins University, North Carolina State University, and the United Kingdom, Canada, Australia, France, Germany, and others.
In addition to serving as Director of BARDA, Dr. Robinson was concurrently appointed Deputy Assistant Secretary, Office of the Assistant Secretary for Preparedness and Response U.S. Department of Health and Human Services (Washington, D.C.), by HHS Secretary Michael Leavitt.
Prior to his public service work at BARDA, he served as Director vaccines at Novavax, Inc. resulting in the discovery and development of more than 12 vaccine candidates. Before entering the pharmaceutical industry, he was an assistant professor in the Department of Microbiology and Immunology at the [:University of Texas]] Southwestern Medical School conducting research on the molecular pathogenesis of herpesviruses and HIV-1. There he developed techniques to grow keratinocytes in tissue culture from fresh skin biopsies.
Spraying Skin Stem Cells onto Burns and Wounds
To date, over 70 patients with various types of second-degree burns have been treated on an experimental basis utilizing the technology underlying the Company’s SkinGun™, which RenovaCare has developed as a potential alternative to skin grafting and other treatment options, such as in-vitro cultured epithelial grafts that require a specialized and expensive external laboratory.
Sprayed with a gentle mist of their own skin cells, many of these patients left the hospital within days, avoiding generally painful skin graft surgeries and potentially weeks of hospitalization. Clinical outcomes of early experimental treatments have been peer-reviewed and published in several medical journals, including Burns and Annals of Plastic Surgery.
Patients who undergo skin grafting, today’s default treatment of care, can remain hospitalized for weeks and even months, and often enduring painful and costly surgeries and prolonged physical therapy. Some of these patients may also suffer from the psychological effects of disfigurement caused by permanent scarring and often cope with the ongoing use of pain medications and protracted joint mobility issues.
RenovaCare products are currently in development. They are not available for sale in the United States. There is no assurance that the Company’s planned or filed submissions to the U.S. Food and Drug Administration will be accepted or cleared by the FDA.
About RenovaCare
RenovaCare, Inc. is developing first-of-its-kind autologous (self-donated) stem cell therapies for the regeneration of human organs. Its initial product under development targets the body’s largest organ, the skin. The company’s flagship technology, the CellMist™ System, uses its patented SkinGun™ to spray a liquid suspension of a patient’s stem cells – the CellMist™ Solution – onto wounds.
RenovaCare is developing its CellMist™ System as a promising new alternative for patients suffering from burns, chronic and acute wounds, and scars. In the US alone, this $45 billion market is greater than the spending on high-blood pressure management, cholesterol treatments, and back pain therapeutics.
For additional information, please call Amit Singh at: 888-398-0202 or visit: http://renovacareinc.com 6)
Esperovax Appoints Dr. Robin Robinson as President and CEO
PLYMOUTH, Michigan
May 1, 2023
/PRNewswire/
Esperovax, Inc. a leading oral RNA vaccine and therapeutic technology company specializing in oral mRNA-based medicines, announced today the appointment of Dr. Robin Robinson as President and Chief Executive Officer (CEO). Dr. Robinson will lead the company from technology discovery and early development into the next stages of pre-clinical/ clinical product development and the company's financial growth.
“Esperovax oral RNA technologies are ripe for further development of selected product candidates in animal and early-stage clinical studies,” said Robinson. “These technologies and supportive data are well-suited to meet vaccine needs for better long-lasting mucosal immunity and to metabolic disease and oncology therapeutic needs for oral RNA drug delivery and gene specific tissue-targeting.”
Added Robinson: “I have followed Esperovax for several years as a member of the Scientific Advisory Board, and I am excited to lead the talented Esperovax team to develop new and better medicines to the global community and to build stronger value for our shareholders through long-term strategic collaborations and industry partnerships.”
Dr. Robinson is a renowned international scientific and public health leader in novel and innovative vaccines and biothreat medical countermeasures as the former Vaccine Director at Novavax, Inc. and the founding Director of the Biomedical Advanced Research and Development Authority (BARDA) in the U.S. Government. Dr. Robinson was cited in 2014 – 2016 as one the Top 50 Influential Persons in Vaccines and in 2018 as one of the top 100 innovators in medicine by The Medicine Maker. A pioneer in the creation of Virus-Like Particle (VLP) vaccines, several of his VLP vaccines are licensed vaccines marketed globally. At BARDA using a public-private partnership model, he led hundreds of early-stage product candidates through advanced clinical and manufacturing development resulting in more than 60 FDA-approved and marketed products to date.
Recently Dr. Robinson led the development of a novel stem cell therapy to treat wounds from a pre-clinical stage product into clinical studies while serving as the Chief Scientific Officer at RenovaCare, Inc. This successful effort required his integration of multi-national R&D, manufacturing, and clinical site partners with regulatory agencies. These previous and current experiences and skills will serve Esperovax well during its evolving growth.
Esperovax Board Chairman Roger Newton commented: “The appointment of Dr. Robinson as CEO marks a notable milestone for Esperovax, an organization committed to addressing unmet medical needs and providing hope to patients worldwide, the meaning of “Esperar” in Esperovax. Through the development of cutting-edge mRNA-based therapies, the company aims to revolutionize the field of medicine. With Dr. Robinson at the helm, Esperovax is poised to deliver on its promise of life-saving therapies that will improve the health and wellbeing of individuals across the globe.”
Esperovax's previous CEO, Dr. David O'Hagan, will continue his scientific leadership in the company's R&D and daily operations.
About Esperovax Esperovax is a cutting-edge vaccine company dedicated to developing innovative oral mRNA-based vaccines and therapeutics. The company is committed to advancing the science of medicine to help people live healthier, happier lives. For more information, please visit Esperovax.com. SOURCE Esperovax 7)